definiens: ) with a Third Party ( as defined in the EC Commitments, the [ * ] Certain confidential information contained in this document, marked by brackets, has been omitted and filedseparately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, asamended . Confidential treatment has been requested with respect to this information . ) governing the research, development, manufacture, sale, marketing, distribution and commercialization of Binimetinib and productscontaining Binimetinib in the EEA and in any jurisdictions where the applicableantitrust authorities have required that [COMPANY] enter into such collaboration or licenseagreement ; and ( b ) subject to customary and reasonable confidentiality and non - use arrangements, provide any potential Suitable Partner with reasonablediligence regarding the research, development, manufacture, sale, marketing, distribution and commercialization of Binimetinib and products containingBinimetinib in the EEA and such additional jurisdictions ; provided, however thatArray shall not be permitted to so execute an Alliance Agreement or so provide anypotential Suitable Partner with any such diligence information that constitutes theConfidential Information of [COMPANY] prior to the adoption of the EC RemedyDecisions . ”(c ) Effective Date